Genmab — Maj 2019
-
stiller
-
I og med Genmab for nylig har informeret de forventer MAIA godkendt i Q2 så er alt jo iorden m.h.t guiding og mon ikke Q1 igen igen bliver en non-event. Dog tror jeg der kan komme positivt angående Dara salg i ROW og opdatering angående salg i Kina som sikkert bliver heftigt

-
-
Det er monoterapi RRMM https://ir.genmab.com/static-files/0bfc1479-b287-4692-a31d-fc5f8e8fc5cd
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind